Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
Dear Cancer Coach.
I was diagnosed by sterotactic biopsy with ductal carcinoma in-situ (DCIS). I had a lumpectomy performed. The surgeon called regarding pathology report there was no more DCIS it had all.
Apparently all of the DCIS had been removed previously with the biopsy.
The biopsy did show some atypical hyperplasia. Margins clear, so now what?
The labs we 10 percent estrogen binding 90 percent progesterone. Any suggestions? Thanks, Diane
Several things. First and foremost, DCIS is not cancer. You can call it pre-cancer, cancer stage 0 or abnormal cells. Yes, DCIS does slightly increase the risk of a breast cancer diagnosis. The adjuvant therapies recommended by your radiologist and oncologist will reduce the risk of a breast cancer diagnosis but only slightly. You must weigh the risks of side effects of radiation and tamoxifen with the possible benefit of reducing your risk of BC diagnosis. I will list all this info below.
Finally there a host of evidence-based, non-toxic therapies that research has shown will also reduce the risk of a full-blown BC diagnosis.
My suggestions are as follows-
To learn more about DCIS and the evidence-based therapies that can help you prevent its spread into invasive breast cancer, please watch the video below:
Let me know if you have any questions.
“DCIS has been classified according to the architectural pattern of the cells (solid, cribriform, papillary, and micropapillary), tumor grade (high, intermediate, and low grade), and the presence or absence of comedo histology. DCIS can be detected on mammograms by examining tiny specks of calcium known as microcalcifications. Since suspicious groups of microcalcifications can appear even in the absence of DCIS, a biopsy may be necessary for diagnosis.
About 20–30% of those who do not receive treatment develop breast cancer. It is the most common type of pre-cancer in women. There is some disagreement as to whether, for statistical purposes, it should be counted as a cancer: some include DCIS when calculating breast cancer statistics while others do not…”
“Similar to Oncotype DX in the adjuvant setting, Oncotype DX DCIS is a 12-panel gene test with a scoring system that categorizes cancers as low, intermediate, or high risk for local tumor recurrence over 10 years following treatment with breast-conserving surgery alone…”
“But there is a more fundamental problem. The absolute risk of recurrence is so small that the higher relative risk of 26 percent is grossly misleading. Absolute numbers are more meaningful: the difference in risk of developing breast cancer is about 0.8 percent, or fewer than one woman in 100. “This is an example of [a finding that is] statistically significant and clinically irrelevant…
A 2015 study of 108,196 women found that 20 years after their DCIS diagnosis, 3.3 percent had died of breast cancer, almost identical to the rate of women generally. And crucially, those who received radiotherapy had the same risk of dying of breast cancer 10 years out as those who did not. “Why should patients use radiation when we know from many studies that it has no effect on mortality?”
A 2015 study found that, six years out, 98.6 percent of women who had surgery were still alive, versus 98.8 percent of those who did not, adding support to the idea that DCIS can be managed with active surveillance…
“In this article, we will review the beneficial effects on bone and lipids and on the reduction of contralateral breast cancer, as well as the data on endometrial cancer to try to answer the following question: do the benefits outweigh the risks?”